ClinicalTrials.gg
CompletedNCT00103857Updated May 5, 2017Results posted

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

A Phase 3 interventional study of Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily) and Comparator: MK0431 100 mg q.d. (q.d. = once daily) in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,208
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
7th of 197
1,208 · median 102
Started
2005
with 3 others
Phase 3
74 of 198
none open now
Registered
7th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment of the 197 interventional ones that give a count, is one of 4 that started in 2005, is one of 74 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus (T2DM) (a specific type of diabetes).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

54-Week Base Study:

  • Patients between the ages of 18 and 78 with Type 2 Diabetes Mellitus (a specific type of diabetes)

    50-Week Extension Study:

  • Patients who complete the 54-week base study are eligible to enter the 50-week extension study

Exclusion criteria

Exclusion Criteria:

  • Patients who do not have Type 2 Diabetes Mellitus (a specific type of diabetes)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
1,208 participants (actual)

Study arms

  • Experimental
    1

    MK0431 100 mg q.d.

    Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily)

  • Active comparator
    2

    Metformin 500 mg b.i.d.

    Drug: Comparator: Metformin 500 mg b.i.d.

  • Active comparator
    3

    Metformin 1000 mg b.i.d.

    Drug: Comparator: Metformin 1000 mg b.i.d.

  • Experimental
    4

    Coadministration of MK0431 and Metformin 50/500 mg b.i.d.

    Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily) · Drug: Comparator: Metformin 500 mg b.i.d.

  • Experimental
    5

    Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.

    Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily) · Drug: Comparator: Metformin 1000 mg b.i.d.

  • Placebo comparator
    6

    Placebo/Metformin 1000 mg b.i.d.

    Drug: Comparator: Placebo (Phase A)/Metformin (Phase B)

  • Experimental
    7

    Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.

    Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.

Interventions

  • MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.

    Also known as: MK0431

  • MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.

  • DrugComparator: Placebo (Phase A)/Metformin (Phase B)

    During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.

  • Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.

  • DrugComparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.

    MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.

  • Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24

    HbA1c is measured as a percent. This change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24

    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

    Time frame: Week 24

  2. Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 24

    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

    Time frame: Week 24

  3. Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54

    HbA1c is measured as a percent. This change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.

    Time frame: Week 54

  4. Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54

    Change from baseline at Week 54 is defined as Week 54 minus Week 0.

    Time frame: Week 54

  5. Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 54

    Change from baseline at Week 54 is defined as Week 54 minus Week 0.

    Time frame: Week 54

  6. Change From Baseline in HbA1c (Hemoglobin A1C) at Week 104

    HbA1c is measured as a percent. This change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent.

    Time frame: Week 104

  7. Change From Baseline in FPG (Fasting Plasma Glucose) at Week 104

    Change from baseline at Week 104 is defined as Week 104 minus Week 0.

    Time frame: Week 104

  8. Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104

    Change from baseline at Week 104 is defined as Week 104 minus Week 0.

    Time frame: Week 104

07

Results

Posted May 19, 2009
Limitations and caveats
Non-serious adverse experience results represent those events included in the primary safety analysis for this study (i.e., events that occurred prior to the initiation of glycemic rescue therapy).

Participant flow

First Patient In: 01-Apr-2005 Last Patient Last Visit: 29-Feb-2008 140 study centers worldwide

54-Week Base Study
Participant flow — 54-Week Base Study
MilestoneSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC
Started179182182190182176117
Completed12212613514814111579
Not completed57564742416138
Withdrew: Adverse event1291165113
Withdrew: Death0000110
Withdrew: Lack of efficacy11148431419
Withdrew: Lost to follow-up54751093
Withdrew: Physician decision1100100
Withdrew: Pregnancy1000101
Withdrew: Protocol violation6424033
Withdrew: Withdrawal by subject1716161510154
Withdrew: Protocol discontinuation criteria2526535
Withdrew: Patient moved0112310
Withdrew: Non-compliance with study procedures1200020
Withdrew: Patient incarcerated0000110
Withdrew: Laboratory reporting error0000100
Withdrew: Site error0000010
Withdrew: Patient intolerance to rescue therapy1000000
50-Week Extension Study
Participant flow — 50-Week Extension Study
MilestoneSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC
Started103107121134122980
Completed65809598101780
Not completed3827263621200
Withdrew: Adverse event2320110
Withdrew: Death0001010
Withdrew: Lack of efficacy26151316880
Withdrew: Lost to follow-up4014330
Withdrew: Physician decision0110000
Withdrew: Pregnancy0010100
Withdrew: Protocol violation1112010
Withdrew: Withdrawal by subject2528330
Withdrew: Protocol discontinuation criteria2232330
Withdrew: Non-compliance with study procedures1001100
Withdrew: Patient moved0012000
Withdrew: Patient scheduled for elective surgery0010000
Withdrew: Reason unspecified0000100

Outcome measures

PrimaryChange From Baseline in HbA1c (Hemoglobin A1C) at Week 24

HbA1c is measured as a percent. This change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.

Time frame:
Week 24
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24
PercentSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24-0.66 (-0.83 to -0.50)-0.82 (-0.98 to -0.66)-1.13 (-1.29 to -0.97)-1.40 (-1.56 to -1.24)-1.90 (-2.06 to -1.74)0.17 (0.00 to 0.33)
SecondaryChange From Baseline in FPG (Fasting Plasma Glucose) at Week 24

Change from baseline at Week 24 is defined as Week 24 minus Week 0.

Time frame:
Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24
mg/dLSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24-17.5 (-24.1 to -10.8)-27.3 (-34.0 to -20.7)-29.3 (-35.9 to -22.6)-47.1 (-53.7 to -40.6)-63.9 (-70.5 to -57.3)5.8 (-1.0 to 12.7)
SecondaryChange From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 24

Change from baseline at Week 24 is defined as Week 24 minus Week 0.

Time frame:
Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 24
mg/dLSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 24-51.9 (-62.3 to -41.5)-53.4 (-63.6 to -43.2)-78.0 (-88.3 to -67.6)-92.5 (-102.6 to -82.5)-116.6 (-126.4 to -106.7)0.3 (-10.4 to 11.0)
SecondaryChange From Baseline in HbA1c (Hemoglobin A1C) at Week 54

HbA1c is measured as a percent. This change from baseline reflects the Week 54 HbA1c percent minus the Week 0 HbA1c percent.

Time frame:
Week 54
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54
PercentSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 54-0.82 (-1.00 to -0.63)-1.01 (-1.18 to -0.83)-1.34 (-1.50 to -1.17)-1.41 (-1.57 to -1.25)-1.80 (-1.96 to -1.65)-1.10 (-1.32 to -0.88)
SecondaryChange From Baseline in FPG (Fasting Plasma Glucose) at Week 54

Change from baseline at Week 54 is defined as Week 54 minus Week 0.

Time frame:
Week 54
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54
mg/dLSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 54-16.0 (-23.2 to -8.7)-29.0 (-35.9 to -22.2)-39.6 (-46.0 to -33.2)-42.5 (-48.6 to -36.3)-55.6 (-61.6 to -49.6)-43.9 (-52.3 to -35.5)
SecondaryChange From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 54

Change from baseline at Week 54 is defined as Week 54 minus Week 0.

Time frame:
Week 54
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 54
mg/dLSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 54-45.9 (-57.2 to -34.6)-58.6 (-69.6 to -47.6)-76.3 (-86.1 to -66.5)-89.6 (-99.2 to -80.0)-107.9 (-117.1 to -98.7)-80.9 (-93.9 to -67.9)
SecondaryChange From Baseline in HbA1c (Hemoglobin A1C) at Week 104

HbA1c is measured as a percent. This change from baseline reflects the Week 104 HbA1c percent minus the Week 0 HbA1c percent.

Time frame:
Week 104
Reported as:
Least squares mean · Percent
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 104
PercentSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in HbA1c (Hemoglobin A1C) at Week 104-1.15 (-1.37 to -0.92)-1.06 (-1.26 to -0.87)-1.34 (-1.51 to -1.17)-1.39 (-1.55 to -1.22)-1.66 (-1.81 to -1.50)-1.39 (-1.63 to -1.15)
SecondaryChange From Baseline in FPG (Fasting Plasma Glucose) at Week 104

Change from baseline at Week 104 is defined as Week 104 minus Week 0.

Time frame:
Week 104
Reported as:
Least squares mean · mg/dL
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 104
mg/dLSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in FPG (Fasting Plasma Glucose) at Week 104-26.8 (-36.2 to -17.4)-41.4 (-49.8 to -33.0)-43.2 (-50.3 to -36.2)-47.5 (-54.3 to -40.7)-57.3 (-63.7 to -50.8)-45.2 (-55.7 to -34.8)
SecondaryChange From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104

Change from baseline at Week 104 is defined as Week 104 minus Week 0.

Time frame:
Week 104
Reported as:
Least squares mean · mg/dL
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104
mg/dLSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.
Change From Baseline in 2-Hour PMG (Post-Meal Glucose) at Week 104-74.1 (-90.3 to -57.9)-72.7 (-87.4 to -58.1)-86.7 (-99.0 to -74.5)-96.2 (-107.8 to -84.6)-110.0 (-120.9 to -99.1)-93.3 (-111.8 to -74.9)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg q.d.———
Metformin 500 mg b.i.d.———
Metformin 1000 mg b.i.d.———
Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.———
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.———
Placebo/Metformin 1000 mg b.i.d.———
Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC———
Most frequent serious events
Showing 10 of 101
Most frequent serious events
EventSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC
Any Cardiac DisordersCardiac disorders2/1791/1823/1823/1903/1824/1760/117
Any Infections And InfestationsInfections and infestations3/1792/1821/1821/1903/1824/1761/117
Any Neoplasms Benign, Malignant And UnspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/1793/1822/1822/1901/1824/1761/117
Any Nervous System DisordersNervous system disorders2/1790/1820/1822/1900/1824/1760/117
Any Injury, Poisoning And Procedural ComplicationsInjury, poisoning and procedural complications1/1791/1824/1821/1902/1821/1760/117
Coronary Artery DiseaseCardiac disorders0/1790/1820/1821/1900/1823/1760/117
Any General Disorders And Administration Site ConditionsGeneral disorders0/1791/1820/1823/1900/1823/1760/117
Any Hepatobiliary DisordersHepatobiliary disorders0/1791/1821/1820/1900/1823/1760/117
Any Gastrointestinal DisordersGastrointestinal disorders1/1790/1821/1821/1902/1822/1760/117
CholelithiasisHepatobiliary disorders0/1790/1821/1820/1900/1822/1760/117
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLC
Any Infections And InfestationsInfections and infestations40/17944/18253/18254/19060/18237/17619/117
Any Gastrointestinal DisordersGastrointestinal disorders19/17923/18242/18231/19035/18217/17618/117
DiarrhoeaGastrointestinal disorders8/17914/18223/18219/19025/18212/17610/117
Any Musculoskeletal And Connective Tissue DisordersMusculoskeletal and connective tissue disorders16/17920/18221/18219/19025/18213/1766/117
Upper Respiratory Tract InfectionInfections and infestations12/17917/18220/18221/19024/18213/1764/117
BronchitisInfections and infestations3/1793/18210/1827/19020/1828/1763/117
Any Nervous System DisordersNervous system disorders9/17913/18220/18217/19019/18210/1764/117
NauseaGastrointestinal disorders2/1796/18219/18210/19012/1824/1767/117
HeadacheNervous system disorders6/1799/18212/18215/19012/1827/1763/117
InfluenzaInfections and infestations8/17911/18214/18211/1909/1825/1763/117

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLCTotal
Mean53.3 ± 10.253.4 ± 10.253.2 ± 9.654.1 ± 10.053.3 ± 9.653.6 ± 10.052.6 ± 10.053.4 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLCTotal
Female8693100851058350602
Male938982105779367606
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLCTotal
White9387106102958144608
Black11129131417985
Hispanic52553955494754351
Asian6141091112163
Other1714181113199101
HbA1c (Hemoglobin A1c)
HbA1c (Hemoglobin A1c)(Percent)Sitagliptin 100 mg q.d.Metformin 500 mg b.i.d.Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d. + Metformin 500 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d.Placebo/Metformin 1000 mg b.i.d.Sitagliptin 50 mg b.i.d + Metformin 1000 mg b.i.d. OLCTotal
Mean8.9 ± 1.08.9 ± 1.08.7 ± 0.98.8 ± 1.08.7 ± 0.98.7 ± 1.011.2 ± 1.29.0 ± 1.2
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 Aug;30(8):1979-87. doi: 10.2337/dc07-0627. Epub 2007 May 7. Erratum In: Diabetes Care. 2008 Aug;31(8):1713. PubMed 17485570 ↗
  • Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2. PubMed 32501595 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2005 to primary completion in Jul 2006, 16 months.

Results were first posted in May 2009, 2 years 9 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2005
First posted
Feb 16, 2005
StartActual
Mar 17, 2005
Primary completionActual
Jul 25, 2006
CompletionActual
Feb 21, 2008
Results first posted
May 19, 2009
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00103857
Responsible party
Sponsor
First posted
Feb 16, 2005
Start date
Mar 17, 2005
Primary completion
Jul 25, 2006
Completion
Feb 21, 2008
Results posted
May 19, 2009
Last update
May 5, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion